Table 3.

The clinical application of serum fibronectin concentration in the assessment of liver fibrosis

Etiology	N	Stage	Cut off	AUC	Se. (%)	Sp. (%)	NPV (%)	PPV (%)	Conclusion	Ref.
Chronic hepatitis B	78		135 ng/mL	0.66	60	71	71	60	Decreased serum fibronectin concentrations in patients with ACHBLF were correlated to inflammation and hepatic injury. However, because of low specificity, the use of fibronectin is limited as an independent prognostic indicator.	(13)
HCV	145	F0-F4	>380 ng/mL		70	73	77	64	In this study, a novel index fibronectin discriminate score (FDS) based on albumin, fibronectin, and APRI was provided. The FDS predicted liver fibrosis with a higher degree of accuracy than fibronectin.	(15)
	Estimation group		> 415 ng/mL		60	58	44	59
	180		>380 ng/mL		72	81	75	79
	Validation group	F0-F4	> 415 ng/mL		72	68	52	84
HCV	126	F0-F3		0.78	75	82			Serum fibronectin showed satisfactory reproducibility and could be used for the differentiation of HCV infected patients with liver fibrosis from those with non-fibrosis.	(26)

N: number of cases, AUC: area under the curve; Se: sensitivity; Sp: specificity; NPV: negative predictive value; PPV: positive predictive value; ACHBLV: acute-on-chronic hepatitis B liver failure; HCV: hepatitis B virus